Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Short-term Investments (2016 - 2017)

Historic Short-term Investments for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q4 2017 value amounting to $25.0 million.

  • Teva Pharmaceutical Industries' Short-term Investments fell 7159.09% to $25.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $25.0 million, marking a year-over-year decrease of 7159.09%. This contributed to the annual value of $25.0 million for FY2017, which is 7159.09% down from last year.
  • As of Q4 2017, Teva Pharmaceutical Industries' Short-term Investments stood at $25.0 million, which was down 7159.09% from $88.0 million recorded in Q4 2016.
  • In the past 5 years, Teva Pharmaceutical Industries' Short-term Investments registered a high of $105.0 million during Q4 2015, and its lowest value of -$366.0 million during Q4 2013.
  • For the 5-year period, Teva Pharmaceutical Industries' Short-term Investments averaged around -$13.2 million, with its median value being $82.0 million (2014).
  • In the last 5 years, Teva Pharmaceutical Industries' Short-term Investments crashed by 925000.0% in 2013 and then surged by 12240.44% in 2014.
  • Teva Pharmaceutical Industries' Short-term Investments (Quarter) stood at -$366.0 million in 2013, then surged by 122.4% to $82.0 million in 2014, then rose by 28.05% to $105.0 million in 2015, then dropped by 16.19% to $88.0 million in 2016, then crashed by 71.59% to $25.0 million in 2017.
  • Its Short-term Investments stands at $25.0 million for Q4 2017, versus $88.0 million for Q4 2016 and $105.0 million for Q4 2015.